La Jolla Pharmaceutical Company
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- La Jolla Pharmaceutical Company, a wholly-owned subsidiary of Innoviva, Inc., commercializes innovative therapies for patients suffering from life-threatening diseases in critical care and infectious disease segments; its marketed products include GIAPREZA (angiotensin II) injection, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for injection, a tetracycline-class antibacterial for the treatment of complicated intra-abdominal infections in patients 18 years of age and older; XACDURO (sulbactam for injection; durlobactam for injection), an antibacterial for difficult-to-treat infections; and ZEVTERA (ceftobiprole medocaril sodium for injection), a cephalosporin antibiotic targeting serious bacterial infections. The company maintains a development pipeline featuring zoliflodacin, an oral antibiotic candidate for uncomplicated gonorrhea that completed its pivotal Phase 3 trial, with an NDA submission anticipated; earlier-stage candidates historically encompassed synthetic fluorocyclines like TP-6076 for multidrug-resistant gram-negative bacteria and TP-271 for respiratory infections. Founded in 1989 and headquartered in Waltham, Massachusetts, La Jolla operates primarily in the United States, with products marketed to hospitals and healthcare providers addressing high unmet needs in antimicrobial resistance and hemodynamic support. In 2022, La Jolla was acquired by Innoviva for approximately $149 million, becoming a key component of Innoviva Specialty Therapeutics and delisted from Nasdaq; subsequent portfolio expansions integrated Entasis Therapeutics' assets including XACDURO and licensing for ZEVTERA from Basilea Pharmaceutica in 2024, alongside recent advancements such as new zoliflodacin data presentations at IDWeek 2025 and product nominations for the 2025 Prix Galien USA awards.
Innoviva Completes Acquisition of La Jolla Pharmaceutical
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating La Jolla Pharmaceuticals Company Buyout
SHAREHOLDER ALERT: Weiss Law Investigates La Jolla Pharmaceutical Company
La Jolla Pharmaceutical Company (LJPC) Stock: Why It Skyrocketed Over 80% Today
Innoviva to Acquire La Jolla Pharmaceutical Company
Moving Average Crossover Alert: La Jolla Pharmaceutical (LJPC)
La Jolla Pharmaceutical (LJPC) Misses Q1 Earnings Estimates
La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2021 and Highlights Corporate Progress
La Jolla Pharmaceutical (LJPC) Reports Q4 Loss, Tops Revenue Estimates
La Jolla Pharmaceutical (LJPC) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
La Jolla Pharma (LJPC) Sees Hammer Chart Pattern: Time to Buy?
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2020
Regardless Of Who Wins The White House, This FTSE 100 Stock Could Benefit
PNC Financial Services Group Inc. Sells 3,271 Shares of Crh Plc (NYSE:CRH)
Concrete and Cement Market to Reach USD 332.2 bn by 2024, Adelaide Brighton Ltd. and Cementir Holding SpA Emerge as a Key Contributors to Growth | Technavio
CRH finance chief announces surprise exit
Sei Investments Co. Increases Stock Position in Crh Plc (NYSE:CRH)
Captrust Financial Advisors Invests $63,000 in Crh Plc (NYSE:CRH)
CRH (LON:CRH) Stock Price Crosses Above Two Hundred Day Moving Average of $2,621.96
COVID-19 Recovery Analysis: Wood-plastic Composites Market | Increasing Infrastructure Investments to Boost the Market Growth | Technavio